Protalix stock rises as biotech set to join Russell 3000 Index

Protalix BioTherapeutics (NYSE:PLX) stock rose ~8% on Tuesday after the company said it is set to join the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective June 26 when U.S. markets open.
The preliminary list of additions were posted May 19.
"We believe that inclusion in the widely referenced Russell U.S. Indexes is another milestone in Protalix's progress, which includes the approval in both the United States and the European Union of PRX–102 for the treatment of adults with Fabry disease," said Protalix's President and CEO Dror Bashan.
Protalix and Chiesi Group's Elfabrio (pegunigalsidase alfa-iwxj) to treat adult patients with Fabry disease was approved in the U.S. earlier this month.